Loading...
Novacyt S.A.
NVYTF•PNK
Healthcare
Medical - Devices
$0.50
$0.00(0.00%)

Over the last four quarters, Novacyt S.A. achieved steady financial progress, growing revenue from $2.56M in Q4 2022 to $8.29M in Q4 2023. Gross profit stayed firm with margins at -11% in Q4 2023 versus 30% in Q4 2022. Operating income totaled -$11.38M in Q4 2023, maintaining a -137% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$8.37M. Net income dropped to -$20.07M, with EPS at -$0.33. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan